New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:45 EDTINSYInsys Therapeutics price target raised to $99 from $50 at JMP Securities
JMP Securities increased its price target on Insys after the company reported higher than expected earnings. The firm expects the company to benefit from continued growth in its Subsys drug and further advances in its pipeline. JMP Securities reiterates an Outperform rating on the stock.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
07:04 EDTINSYInsys in-licenses cannabinoid inhalation technology
Insys Therapeutics announced that it has entered into an exclusive license agreement and partnership with U.K. based Senzer Ltd. for the development of inhaled synthetic pharmaceutical cannabinoid products including dronabinol and cannabidiol using Senzer's proprietary inhalation delivery technology. Senzer has exclusively licensed all proprietary inhalation delivery technology in the field of Cannabinoid molecules held by Kind Consumer Holdings Limited, a UK based healthcare research and development company focused on inhalation technologies. The Kind Consumer inhalation technology has been recently approved by the Medicines and Healthcare products Regulatory Agency in the United Kingdom as a licensed medicine for smoking cessation. Insys and Senzer will work towards the development of synthetic pharmaceutical THC and CBD inhaled products under the guidance of the U.S. Food and Drug Administration using the same inhalation technology as used in the Voke Inhaler product.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use